Phage therapy in the management of respiratory and pulmonary infections: a systematic review by Patience Sarkodie-Addo, Abdul-Halim Osman, Bill Clinton Aglomasa, Eric S. Donkor

“…Consequently, there is a need for additional clinical studies to establish standardised pharmacokinetic elements and an overall protocol for PT. …”
Get full text

Bis(7)-harmine derivatives as potential multi-target anti-Alzheimer agents by Hongtao Du, Hongtao Du, Hongtao Du, Fang Ma, Fang Ma, Yuanyuan Cao, Miaoyan Bai, Xinyi Gao, Ziyi Yang, Yang Xu, Yan Yan, Yan Yan

“…Furthermore, predicted ADMET results suggested that 6d, 8c, and 8d possessed favorable pharmacokinetic properties and demonstrated low toxicity levels. …”
Get full text

Ferula communis leaf extract: antioxidant capacity, UHPLC–MS/MS analysis, and in vivo and in silico toxicity investigations by Imad Ed-Dahmani, Mohamed El Fadili, Ghizlane Nouioura, Fahd Kandsi, Yassine El Atki, Hatem A. Abuelizz, Raffaele Conte, Fatima Zahra Lafdil, Abdeslam Taleb, Abdelfattah Abdellaoui, Mustapha Taleb

“…UHPLC–tandem mass spectrometry (MS/MS) analysis of the extract highlights the presence of 11 compounds, the most abundant of which is p-hydroxybenzoic acid, representing 53.65%. The predicted pharmacokinetic characteristics of absorption, distribution, metabolism, excretion, and toxicity (ADMET) attest to the well-absorbed nature of the isolated compounds, with human intestinal absorption (HIA) varying from 42% for arbutin (M3) to 100% for ursolic acid (M4).ConclusionIn conclusion, the leaves of Ferula communis are a good source of natural antioxidants and phenolic compounds. …”
Get full text

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metast... by Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Michael P Brown, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski

“…Objectives included assessment of safety, antitumor activity, pharmacodynamics, and pharmacokinetic profile.Results Fifty-eight participants started treatment. …”
Get full text

Evaluating the efficacy of carbetocin versus oxytocin for preventing intraoperative blood loss, early postpartum hemorrhage, and maintaining a favorable hemodynamic profile in lowe... by Bisma Fayaz, Raja Suhail Shounthoo, Ajaiz Rasool, Saima Wani, Showkat Ahmad Gurcoo

“…However, their use is compounded by the accompanying side effects, hence the need for uterotonic agents with relatively better pharmacokinetic and pharmacodynamic profile continues. …”
Get full text

Computational insights into Sitahe (Leuconotis eugenifolia) bioactive compounds: A promising approach for radioprotection through p53 inhibition by Dian Pribadi Perkasa, Iin Kurnia, Taufik Muhammad Fakih, Teja Kisnanto, Dwi Ramadhani, Harry Nugroho Eko Surniyantoro, Boky Jeanne Tuasikal, Alfian Mahardika Forentin, Mukh Syaifudin

“…Although these in silico and MD results are promising, further validation through in vitro and in vivo studies is essential to confirm their therapeutic potential and optimize their pharmacokinetic properties. This study positions Sitahe phytochemicals, particularly baurenol, as promising candidates for the development of novel radioprotective agents in cancer treatment.…”
Get full text

Identification of natural compound inhibitors for substrate-binding site of MTHFD2 enzyme: Insights from structure-based drug design and biomolecular simulations by Nisarg Rana, Priyanka Solanki, Rukmankesh Mehra, Anu Manhas

“…After drug-likeness and pharmacokinetic filtering, 209 molecules were docked into the active site of the enzyme, and 20 candidates were shortlisted based on docking score and crucial interactions with residues Asn87, Lys88, Gly310, and Gln132. …”
Get full text

SUCCESSFUL REGISTRATION OF DOMESTIC BIOANALOGUE OF BEVACIZUMAB – NEW OPPORTUNITIES FOR EFFECTIVE TREA TMENT OF PATIENTS WITH NON-SQUAMOUS CELL NON-SMALL CELL LUNG CANCER by S. V. Orlov, S. N. Fogt, M. S. Shustova

“…During the study period the incidence of adverse events, including severe adverse events (grade 3–4 according to CTCAE) related with the investigational drugs, did not have statistically significant differences in both study arms.The drug "Avegra®" in direct comparison to "Avastin®" demonstrated equal efficacy, similar safety and immunogenicity profile, equal pharmacokinetic characteristics. Based on the results of the clinical study the first biosimilar of bevacizumab — drug "Avegra®" was successfully registered in Russian Federation in November 2015 and can be recommended for use in clinical practice.…”
Get full text

High power impulse magnetron sputtering deposited virucide and antibacterial CrN-Cu films and the durability of the antimicrobial activity by Santiago Domínguez-Meister, Janire Mediavilla, Anastasia Dianova, Noelia Álvarez, Sara Insausti, Edurne Rujas, Jose L. Nieva, Marta Brizuela, Iñigo Braceras

Get full text

Protective and Ameliorative Effects of Hydroethanolic Extract of Piper nigrum (L.) Stem against Antiretroviral Therapy-Induced Hepatotoxicity and Dyslipidemia in Wistar Rats by Doreen Enyang, Mubo A. Sonibare, Armelle D. Tchamgoue, Lauve R. Y. Tchokouaha, Fanta S. Yadang, Gael N. Nfor, Christelle W. Kom, Patrick D. H. Betote, Cedric F. Tchinda, Steveng S. K. Tiogo, Gabriel A. Agbor

“…Further studies are necessary to understand the pharmacokinetic interactions between ART and PNS.…”
Get full text

Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator by Rahma Aly, Shoukath Sulthana, Robert Beaudoin, Ayman K. Hamouda, Santosh Aryal

“…Given the superiority of the nanoparticulate system in drug delivery and the unique role of CMPI, we hope this study will help in the development of nAChR PAM formulations that have superior pharmacokinetic profiles, especially their brain bioavailability.…”
Get full text

Molecular Docking Appraisal of Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment by Magdalene Eno Effiong, Mercy Bella-Omunagbe, Israel Sunmola Afolabi, Shalom Nwodo Chinedu

“…The drug likeness, pharmacokinetic, and pharmacodynamic features of prospective docking leads were all anticipated. …”
Get full text

Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Su... by Prativa Sahoo, Paul Frankel, Julie Ressler, Margarita Gutova, Alexander J. Annala, Behnam Badie, Jana Portnow, Karen S. Aboody, Massimo D’Apuzzo, Russell C. Rockne

“…Plasma volume (Vp), permeability (Ktr), and leakage (λtr) perfusion parameters were calculated by fitting a pharmacokinetic model to the DCE-MRI data. The contrast-enhancing (CE) volume was measured from the last dynamic phase acquired in the DCE sequence. …”
Get full text

Development of highly bioactive long-acting recombinant porcine FSH for batch production management of sows by Jiawei Zhang, Lei Shi, Xiaorong Zhong, Yunhe Bai, Jun Dou, Lu Zhang, Xiaochao Shi, Bingchun Wu, Zemin Tan, Lin Yan, Jinku Yu, Jingru Zhang, Guo Han, Jiansheng Xiong, Hua Zhang, Xingyuan Cao, Haoshu Luo

“…In the current study, we developed a novel long-acting recombinant porcine FSH (rpFSH-pFc) consisting of porcine FSH and porcine fragment crystallizable (Fc) via (G4S)3 linker by using the available protein fusion technology to control the follicular development and maturation. The results of pharmacokinetic studies indicated that rpFSH-pFc exhibited a prolonged half-life in both rats and sows. …”
Get full text

Single-nucleotide polymorphisms in dizygotic twin ovine fetuses are associated with discordant responses to antenatal steroid therapy by Erin L. Fee, Haruo Usuda, Sean W. D. Carter, Hideyuki Ikeda, Tsukasa Takahashi, Yuki Takahashi, Yusaku Kumagai, Michael W. Clarke, Demelza J. Ireland, John P. Newnham, Masatoshi Saito, Sebastian E. Illanes, Binny Priya Sesurajan, Liang Shen, Mahesh A. Choolani, Gokce Oguz, Adaikalavan Ramasamy, Sara Ritchie, Andrew Ritchie, Alan H. Jobe, Matthew W. Kemp

“…We aimed to test the degree of concordance in preterm lung function, and correlate this with genomic, transcriptomic, and pharmacokinetic variables in preterm dizygotic twin ovine fetuses. …”
Get full text

Curcumin encapsulated in PAMAM dendrimers for the therapeutic treatment of ischemic stroke in rats by Justin Stadler, Justin Stadler, Justin Stadler, Lucas G. Garmo, Lucas G. Garmo, Lucas G. Garmo, David Doyle, David Doyle, David Doyle, Chin-I. Cheng, Garrett Richardson, Garrett Richardson, Zain Waheed, Zain Waheed, Tim Tofan, Bhairavi Srinageshwar, Bhairavi Srinageshwar, Bhairavi Srinageshwar, Ajit Sharma, Robert B. Petersen, Gary L. Dunbar, Gary L. Dunbar, Gary L. Dunbar, Julien Rossignol, Julien Rossignol, Julien Rossignol

“…Polyamidoamine (PAMAM) dendrimers are nanomolecules commonly used in biomedical applications due to their ability to encapsulate small-molecules and improve their pharmacokinetic properties. Curcumin is known to have anti-inflammatory and antioxidant effects yet suffers from poor solubility and bioavailability. …”
Get full text

The Identification and synthesis of metabolites of 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide by Alexander L. Khokhlov, Ilya I. Yaichkov, Anton A. Shetnev, Valeria A. Panova, Julia A. Efimova, Sergey A. Ivanovskiy, Mikhail K. Korsakov, Nikita N. Volkhin, Sergey S. Petukhov

“…Introduction: 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide is a new selective type II carbonic anhydrase inhibitor with local action through instillation into the eyes. For a complete pharmacokinetic study of this drug, it is necessary to detect and synthesize its metabolites for their systemic exposure evaluation. …”
Get full text

In vivo brain delivery of BBB-enabled iduronate 2-sulfatase in rats by Will J. Costain, Arsalan S. Haqqani, Greg Hussack, Henk van Faassen, Etienne Lessard, Binbing Ling, Eric Brunette, Dao Ly, Hung Fang, Jennyfer Bultinck, Steven Geysens, Gwenda Pynaert, Kathleen Piens, Stefan Ryckaert, Franck Fudalej, Wouter Vervecken, Danica Stanimirovic

“…Methods: Single-domain antibody (sdAb)-enzyme fusion protein constructs were prepared in Yarrowia lipolytica. sdAb affinity and BBB permeability were characterized using SPR and an in vitro rodent BBB assay, respectively. In vivo pharmacokinetic (PK) analysis was performed in rats. Quantification of fusion protein amounts were performed using LC-MS. …”
Get full text

Micronutrient dose response (MiNDR) study among women of reproductive age and pregnant women in rural Bangladesh: study protocol for double-blind, randomised, controlled trials by Tahmeed Ahmed, Hasmot Ali, Michael Rosenblum, Daniel J Erchick, Towfida Jahan Siddiqua, Rezwanul Haque, Parul Christian, Sarah Baker, Eleonor Zavala, Kerry J Schulze, SM Tafsir Hasan, Khalid Bin Ahsan, Sulagna Bandyopadhyay, Hasan Mahmud Sujan, Md. Hafizur Rahman, Katherine K Stephenson, Ximing Ge, Ethan K Gough, Brooke Langevin, Lee Shu Fune Wu, Brian Dyer, Anjan Kumar Roy, Mohammad Jubair, Amena Al Nishan, Mathangi Gopalakrishnan, Klaus Kraemer

“…Outcomes are biomarkers of nutrient status. Pharmacokinetic modelling will estimate micronutrient intakes at which sufficiency for each nutrient without excess is achieved. …”
Get full text

INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses by Jason Ho, Chelsie Macedo, Garrett Cyprus, Rajay Pandit, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago, Emily Rowell, Florian J Sulzmaier, John C Timmer, Brendan P Eckelman

“…Despite promising activity in a subset of patients, wider therapeutic utility of IL-2 (aldesleukin) has been hampered by severe dose-limiting toxicities, the expansion of immunosuppressive regulatory T cells and a poor pharmacokinetic (PK) profile. Recent engineering efforts, including non-α IL-2 variants, have lowered the toxicity profile, but have yet to induce meaningful antitumor activity in a wider patient population.Methods We engineered INBRX-120, a CD8α-targeted Cisleukin™ molecule consisting of an affinity tuned IL-2 (IL2-x) connected to two high affinity CD8α-specific single domain antibodies via an effector-silenced Fc domain. …”
Get full text